染色体核型分析 中国就医指南

Chromosome Karyotype Analysis is not a disease but a fundamental diagnostic cytogenetic laboratory test used primarily in hematology to detect numerical and structural abnormalities in human chromosomes. It involves culturing peripheral blood lymphocytes (or bone marrow aspirate cells), arresting mitosis at metaphase, staining chromosomes (typically with G-banding), and analyzing their number, size, shape, and banding patterns under high-resolution microscopy. This test is critical for diagnosing, classifying, prognosticating, and monitoring hematologic malignancies—including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and lymphomas—as well as constitutional disorders like Down syndrome or Fanconi anemia when hematologic manifestations are present. Pathogenesis of associated conditions varies: in CML, the hallmark t(9;22) translocation generates the BCR-ABL1 fusion gene driving uncontrolled tyrosine kinase activity; in AML, recurrent abnormalities such as inv(16), t(8;21), or -7 reflect clonal evolution and disrupted hematopoietic differentiation. Epidemiologically, karyotypic abnormalities occur in >90% of AML and >85% of MDS cases, with incidence rising sharply after age 60. Risk factors for developing karyotype-abnormal hematologic disorders include prior chemotherapy or radiation (therapy-related MDS/AML), benzene exposure, smoking, inherited bone marrow failure syndromes, and advanced age. While Chromosome Karyotype Analysis itself carries no direct morbidity, delays or inaccuracies in its performance can significantly impair clinical decision-making—leading to inappropriate therapy selection, missed opportunities for targeted agents (e.g., tyrosine kinase inhibitors), or inaccurate risk stratification. Quality of life impact is therefore indirect but profound: patients with abnormal karyotypes often face more aggressive disease courses, higher relapse rates, reduced transplant eligibility, and greater psychological burden due to uncertainty and poorer prognoses. The test requires specialized infrastructure, trained cytogeneticists, and 7–14 days for completion—making timely access essential. Though largely supplanted by faster molecular methods (e.g., FISH, PCR, NGS) for specific targets, karyotyping remains the gold standard for genome-wide, unbiased detection of novel or complex rearrangements and is indispensable for comprehensive hematologic evaluation per WHO and ELN guidelines.

# 染色体核型分析（血液科）治疗方案与费用明细指南

一、非手术/保守/检验方案

适用人群：疑似白血病、MDS、淋巴瘤、骨髓增殖性肿瘤等需细胞遗传学评估者。

• •常规G显带核型分析（48–72小时培养）：¥1,800–¥2,600（含外周血/骨髓标本处理、中期分裂相计数≥20个、标准ISCN报告）
• •高分辨显带（≥550条带）+荧光原位杂交（FISH）补充：¥3,200–¥4,500（适用于复杂核型或微缺失筛查）
• •快速FISH检测（如BCR::ABL1、PML::RARA）：¥1,200–¥1,800/项

二、手术/介入相关配套方案

注：核型分析本身为实验室诊断技术，无手术或微创操作；其标本采集依赖骨髓穿刺（属有创操作，非治疗手段）。

• •骨髓穿刺活检（含涂片+活检+流式初筛）：¥1,500–¥2,300（术前凝血功能、血常规、心电图等基础检查¥300–¥500）

三、特殊复杂场景方案

• •难治复发血液肿瘤的多次动态核型监测（每3–6月）：¥2,000–¥3,000/次
• •嵌合体分析或微小残留病（MRD）联合核型验证：¥4,800–¥6,500（含NGS辅助验证）

四、方案快速选择指南

• •初筛确诊：选常规G显带（¥1,800–¥2,600）
• •高危/疑似复杂核型：选高分辨+核心FISH（¥3,200–¥4,500）
• •预算有限且临床高度提示特定融合基因：单靶点FISH（¥1,200起）
• •临床试验入组或MRD动态评估：全套动态监测组合（¥4,800+/次）